Floatz logo

EXEMESTANE

BRCA2 Mutation

Dana-Farber Cancer InstituteSmall moleculePhase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
81/ 100

Competitive context

30 Active assets in the BRCA2 Mutation cohort.

Asset / SponsorPhaseRating
Olaparib
M.D. Anderson Cancer Center
Phase 3BB
Veliparib
The University of Texas Health Science Center at San Antonio
Phase 2BB
Olaparib
GBG Forschungs GmbH
Phase 3BB
Talzenna
Brown University
Phase 3BB
Ovitrelle
University Hospital, Ghent
Phase 4BB

View all 50 →

Same molecule, other indications

EXEMESTANE is also rated in:

estrogen-receptor positive breast cancerDormant
BBB
Indicative ·
75 / 100
View asset →
ER+ Breast CancerDormant
BBB
Indicative ·
75 / 100
View asset →
hormone receptor-positive breast cancerDormant
BBB
Indicative ·
75 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →